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Abstract
Background: To assess the efficacy and safety of fruquintinib, a vascular endothelial growth factor receptor (VEGFR)
inhibitor, in metastatic colorectal cancer (mCRC) patients.
Methods: A phase Ib open-label study and phase II randomized, placebo-controlled trial compared the efficacy of
fruquintinib plus best supportive care (BSC) with placebo plus BSC in mCRC patients with ≥2 lines of prior therapies.
The primary endpoint was progression-free survival (PFS).
Results: In the phase Ib study, 42 patients took fruquintinib 5 mg for 3 weeks on/1 week off. The median PFS was 5.
80 months, and the median overall survival (OS) was 8.88 months. In the phase II study, 71 patients were randomized
(47 to fruquintinib, 24 to placebo). PFS was significantly improved with fruquintinib plus BSC (4.73 months; 95%
confidence interval [CI] 2.86–5.59) versus placebo plus BSC (0.99 months; 95% CI 0.95–1.58); (hazard ratio [HR] 0.30; 95%
CI 0.15–0.59; P < 0.001). The median OS was 7.72 versus 5.52 months (HR 0.71; 95% CI 0.38–1.34). The most common
grade 3–4 adverse events were hypertension and hand-foot skin reaction.
Conclusions: Fruquintinib showed a significant PFS benefit of 3.7 months in patients with treatment-refractory mCRC.
The safety profile was consistent with that of VEGFR tyrosine kinase inhibitors. A randomized phase III confirmatory
study in mCRC is underway.
Trial registration: NCT01975077 and NCT02196688
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Background
In patients with metastatic colorectal cancer (mCRC),
addition of anti-vascular endothelial growth factor (VEGF)
and anti-endothelial growth factor receptor (EGFR) biologic
agents to chemotherapy regimens, either in the first or sec-
ond line, improves overall survival (OS), progression-free
survival (PFS), and anti-tumor response compared with
chemotherapy alone [1–3]. However, patients frequently
develop resistance and ultimately experience disease pro-
gression, highlighting a demand for more therapeutic strat-
egies after failure of standard chemotherapy [4, 5].
Angiogenesis is an important hallmark of cancer de-
velopment and progression. The VEGF and vascular epi-
dermal growth factor receptor (VEGFR) signaling
pathways strongly promote tumor growth and metasta-
sis. Inhibition of these pathways has demonstrated
strong clinical anti-tumor activity against multiple types
of cancer, leading to the successful approval of both
monoclonal antibody drugs and small molecule VEGFR
inhibitors [6–8]. For instance, bevacizumab, a VEGF-
directed monoclonal antibody, has been approved for
the treatment of mCRC [9]. Recently, regorafenib has
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been approved by the US Food and Drug Administration
based on the results from the CORRECT study [10].
Fruquintinib is a potent and highly selective small
molecule inhibitor of VEGFR-1, VEGFR-2, and VEGFR-3
tyrosine and has shown strong anti-tumor activity in
various preclinical models [11, 12]. In phase I trials,
fruquintinib demonstrated good pharmacokinetic prop-
erties, tolerable safety, and promising anti-tumor activity
against multiple tumor types [13]. A further two-
regimen comparison study was carried out [14], and a
regimen of 5 mg once daily oral dose on a 3-week-on/1-
week-off treatment cycle was determined as the recom-
mended phase II dose (RP2D). We report here data on a
phase Ib expansion trial (NCT01975077) and a random-
ized, double-blind, placebo-controlled, multicenter phase
II trial (NCT02196688) to further assess the safety and
efficacy of fruquintinib at the RP2D in patients with
mCRC who failed at least two prior standard treatments.
Methods
Study design and participants
We conducted an open-label phase Ib trial in two hospi-
tals (NCT01975077) and a randomized, double-blind,
placebo-controlled phase II trial in eight hospitals
(NCT02196688) in China. Most of the inclusion and ex-
clusion criteria were common to both the studies. Pa-
tients were eligible to participate when they had
histological or cytological documentation of adenocar-
cinoma of the colon or rectum. Patients had to have re-
ceived at least a second-line standard therapy, including
fluoropyrimidine, oxaliplatin, or irinotecan-based regi-
mens and to have disease progression within 3 months
after the last administration of the last standard therapy
or to have stopped such therapy due to unacceptable
toxicities. Pre-treatment with EGFR and VEGF inhibitors
(bevacizumab and aflibercept) were allowed but were
not mandatory.
Patients had to be aged between 18 and 75 years and
have an Eastern Cooperative Oncology Group perform-
ance status of 0 or 1, life expectancy of at least
12 weeks, and adequate bone marrow, liver, and renal
function at the start of the trial. Patients could not par-
ticipate if they had previously received any VEGFR in-
hibitors (regorafenib, ramucirumab, apatinib, axitinib,
famitinib, or other tyrosine kinase inhibitors) or had
other uncontrolled medical disorders. Additional files 1
and 2 show full inclusion and exclusion criteria for both
of the studies.
These studies were conducted in accordance with the
laws and regulations in China regarding patient protec-
tion. The studies were approved by the independent eth-
ics committees of each involved institution. Informed
consent was obtained from all the participants.
Randomization and treatment
Patients who met the eligibility criteria for the phase Ib
study took fruquintinib 5 mg once daily, for 3 weeks on
and 1 week off. In the phase II trial, the eligible partici-
pants were randomly assigned in a 2:1 ratio to receive fru-
quintinib plus BSC or placebo plus BSC. The participants,
investigators, and the study funder were masked to treat-
ment group assignment. Randomization was performed
centrally using the interactive web response system
(IWRS), and no stratified randomization was performed.
Unblinding could occur for individual patients via the
IWRS in the case of emergencies only, and serious adverse
events (AEs) did not necessarily precipitate immediate
unblinding. All eligible participants repeated the 28-day
treatment cycle until disease progression, death, unaccept-
able toxicity, withdrawal of consent by the patient, or deci-
sion by the treating physician that discontinuation would
be in the patient’s best interest. The primary study end-
point was PFS.
Toxicity was graded using the National Cancer Institute-
Common Terminology Criteria for Adverse Events version
4.03. Tumor assessment was performed every 8 weeks in
the phase Ib trial and every 4 weeks during the first 4 cycles
and every 8 weeks thereafter in the phase II trial until dis-
ease progression, which was based on computed tomog-
raphy and/or magnetic resonance imaging evaluation as
defined by the Response Evaluation Criteria In Solid
Tumors version 1.1.
We allowed predefined treatment modifications to man-
age clinically significant toxicity. Patients who needed dose
reductions could not re-escalate. The detailed treatment
protocols are provided in Additional files 1 and 2.
Statistical analysis
No formal statistical hypothesis testing was planned for
the phase 1b study, and the planned primary population
for the evaluation of efficacy was the intent-to-treat (ITT)
population.
Based on the anti-tumor efficacy observed for fruquinti-
nib in the phase Ib trial, the placebo-controlled phase II
study was designed to have 67% statistical power to detect
a 50.0% increase in the median PFS, assuming a 2-month
median PFS for the placebo group. Assuming a two-sided
overall α of 0.05, statistical power of 67%, randomization
ratio of 2:1 between fruquintinib and placebo, and no in-
terim analyses during the study, 6 months had to elapse
after the last patient enrolled for the primary endpoint
analysis of PFS and until mature OS data could be ob-
tained for 80% of the patients for the final analysis. We
planned to randomize approximately 70 patients.
All statistical analyses were performed using SAS (ver-
sion 9.2). PFS and OS were compared between the treat-
ment groups using a stratified log-rank test; HRs (with
95% confidence interval [CI]) were calculated using the
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Cox proportional hazards model, adjusting for stratifica-
tion factors, and Kaplan–Meier survival estimates were
calculated for each treatment group. The stratified fac-
tors included previous chemotherapy lines (2 versus ≥3),
previous treatment with VEGF-targeting drugs (yes ver-
sus no), and liver metastases (yes versus no).
Results
Phase Ib trial
The demographic and baseline characteristics for the 42
participants with mCRC who were enrolled into the phase
Ib study between December 26, 2012, and January 24,
2014, are shown in Table 1.
Thirty-one (73.8%) participants completed at least
three treatment cycles in 12 weeks, and 28 (66.7%) par-
ticipants completed at least four treatment cycles in
16 weeks. Dose reduction and interruption was neces-
sary in 20 participants (47.6%).
The median PFS was 5.80 months (95% CI 4.01–7.60),
and the median OS was 8.88 months (95% CI 7.53–
15.53). Four participants had partial response (PR) with
an objective response rate of 9.5%, and 28 participants
had stable disease for at least 8 weeks, with a disease
control rate (DCR) of 76.2%. The treatment efficacy is
summarized in Table 2.
Treatment-related treatment-emergent AEs (TEAEs)
were reported in all 42 participants. The most common
TEAEs of grade 3 or higher were hypertension (21.4%),
hand-foot skin reaction (HFSR, 9.5%), and diarrhea
(9.5%). Overall, fruquintinib was permanently discontin-
ued in five participants (11.9%) due to related TEAEs,
including skin lesion (n = 1), chest pain (n = 1),
hemoptysis (n = 1), pancreatitis (n = 1), and proteinuria
(n = 1). The incidences of grade 3 or higher TEAEs re-
lated to the study drugs are summarized in Table 3. Only
one death, of a patient with lung metastasis who had
fatal hemoptysis, was considered to be possibly treat-
ment related by the investigator. The most common
TEAEs needing treatment modification (treatment inter-
ruption or dose reduction) were thrombocytopenia
(11.9%), HFSR (11.9%), and hypertension (9.5%).
Phase II trial
Between April 1, 2014, and August 20, 2014, 93 patients
were screened and 71 patients were randomized to re-
ceive fruquintinib (n = 47) or placebo (n = 24). All 71
participants underwent treatment for efficacy and safety
analyses (Fig. 1).
The baseline characteristics for all randomized pa-
tients are shown in Table 1. In general, the two groups
were well balanced in terms of baseline demographics
and oncology disease history.
Participants in the fruquintinib group were treated for
a longer period than were those in the placebo group,
with mean treatment durations (from the first dose to
the end of treatment) of 3.2 versus 0.8 months, respect-
ively. Dose modifications were required in 29 (61.7%) of
47 participants who received fruquintinib and 7 (29.2%)
of 24 participants who received placebo. AEs were the
most frequent reasons for dose modification.
PFS was significantly prolonged for patients who were
treated with fruquintinib compared with patients who
received placebo (stratified HR 0.30; 95% CI 0.15–0.59;
two-sided P < 0.001; Fig. 2), which was consistent with
the results of a blinded independent central review
(stratified HR 0.26; 95% CI 0.14–0.50; two-sided P <
0.001). The median PFS was 4.73 months (95% CI 2.86–
5.59) in the fruquintinib group and 0.99 months (95% CI
0.95–1.58) in the placebo group. Pre-specified subgroup
analyses showed significantly superior PFS in the
fruquintinib group in most of the subgroups examined
(Additional file 3). Patients who received fruquintinib
showed a trend of prolonged median OS (7.72 months)
compared with those who received placebo
(5.52 months); however, the difference was not signifi-
cant (stratified HR 0.71; 95% CI 0.38–1.34; Fig. 3). Only
one patient (2.1%) in the fruquintinib group achieved
PR. The DCR was significantly higher in the fruquintinib
group than in the placebo group (68.1% versus 20.8%;
two-sided P < 0.001). The waterfall plots for tumor re-
sponses are shown in Additional file 4. The summary of
drug efficacy is shown in Table 2.
All 47 (100%) participants in the fruquintinib group
and 21 (87.5%) of the 24 participants in the placebo
group had AEs; the AEs were deemed treatment-related
in 44 (93.6%) participants in the fruquintinib group and
14 (58.3%) participants in the placebo group. The most
common (incidence >5%) treatment-related grade 3 or
higher TEAEs were hypertension (29.8%) and HFSR
(14.9%). The summary of grade 3 or higher treatment-
related TEAEs is shown in Table 3. Frequencies of AEs
leading to death, irrespective of relationship to study
drug, were similar, at three in the fruquintinib group
(one [2.1%] upper gastrointestinal hemorrhage, one
[2.1%] bilirubin increased, and one [2.1%] hemoptysis)
and two in the placebo group (one [4.3%] sudden death
and one [4.3%] hepatic coma). Serious AEs occurred in
12 (25.5%) of the 47 participants receiving fruquintinib
and 5 (20.8%) of the 24 participants receiving placebo.
Treatment was interrupted because of AEs in 15 (34.0%)
patients in the fruquintinib group and in 4 (16.7%) in
the placebo group. The study dose was reduced due to
AEs in 13 (27.7%) participants in the fruquintinib group
and none in the placebo group. The common AEs that
required treatment modification were HFSR (17.0%),
hypertension (12.8%), and diarrhea (4.3%).
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(n=42) Fruquintinib group (n=47) Placebo group (n=24) P value
Age (years)
Median, range 55.5, 33.0–70.0 50.0, 25.0–69.0 54.0, 38.0–70.0 0.090
Gender
Male 25 (59.5) 35 (74.5) 17 (70.8) 0.743
Female 17 (40.5) 12 (25.5) 7 (29.2)
Baseline ECOG PS score
0 8 (19.0) 6 (12.8) 5 (20.8) 0.374
1 34 (81.0) 41 (87.2) 19 (79.2)
Duration from first metastasis Diagnosis to randomization
≤18 months NA 20 (42.6) 14 (58.3) 0.208
>18 months NA 27 (57.4) 10 (41.7)
Prior treatment line on or above metastatic disease
2–3 18 (42.9) 30 (63.8) 17 (70.8) 0.555
>3 24 (57.1) 17 (36.2) 7 (29.2)
Previous chemotherapy lines
2 5 (11.9) 12 (25.5) 7 (29.2) 0.743
≥3 37 (88.1) 35 (74.5) 17 (70.8)
Prior VEGF inhibitor treatment
Yes 10 (23.8) 15 (31.9) 7 (29.2) 0.412
No 32 (76.2) 29 (61.7) 17 (70.8)
Unknown 0 3 (6.4) 0
Primary site
Colon 21 (50.0) 24 (51.1) 13 (54.2) 0.804
Rectal 20 (47.6) 23 (48.9) 11 (45.8)
Cecum 1 (2.4) 0 0
Metastatic site
Single 5 (11.9) 2 (4.3) 2 (8.3) 0.481
Multiple 37 (88.1) 45 (95.7) 22 (91.7)
Liver metastasis
Yes 29 (69.0) 29 (61.7) 17 (70.8) 0.446
No 13 (31.0) 18 (38.3) 7 (29.2)
ECOG PS Eastern Cooperative Oncology Group performance status, VEGF vascular endothelial growth factor, NA not available
Table 2 Treatment efficacy in the phase Ib and the phase II trials
Phase Ib Phase II
(N=42) Fruquintinib group (N=47) Placebo group (N=24) P value
Median PFS months, 95% CI 5.80, 4.01 to 7.60 4.73, 2.86 to 5.59 0.99, 0.95 to 1.58 <0.001
Median OS months, 95% CI 8.88, 7.53 to 15.53 7.72, 6.90 to 10.28 5.52, 3.61 to 11.30 0.29
CR No. (%) 0 0 0
PR No. (%) 4 (9.5) 1 (2.1) 0
SD No. (%) 28 (66.7) 31 (66.0) 5 (20.8)
PD No. (%) 7 (16.7) 12 (25.5) 17 (70.8)
Not evaluable, No. (%) 3 (7.1) 2 (4.3) 1 (4.2)
No post-baseline assessment 0 1 (2.1) 1 (4.2)
ORR No. (%), 95% CI 4 (9.5) 1 (2.1), 0.1 to 10.7 0, 0.0 to 12.6 0.45
DCR No. (%), 95% CI 32 (76.2) 32 (68.1), 53.6 to 80.8 5 (20.8), 8.6 to 40.6 <0.001
P values are the results of stratified analyses for comparisons between the fruquintinib group and placebo group in the phase II trial.
ORR = CR + PR, DCR = CR + PR + SD
CI confidence interval, No. number of participants, PFS progression-free survival, OS overall survival, CR complete response, PR partial response, SD stable disease,
PD progressive disease, ORR objective response rate, DCR disease control rate
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Discussion
In the phase II trial, fruquintinib significantly prolonged
PFS to approximately 4.7 versus 1.0 month for placebo.
This supports the significantly higher DCR in the fruquin-
tinib group. Moreover, a blinded independent central re-
view of this randomized phase II study confirmed the PFS
benefit conferred by fruquintinib (3.71 versus 0.95 months,
Additional file 5). A similar anti-tumor efficacy with a 5.8-
month PFS was observed for patients who were enrolled
in the phase Ib trial. These two studies show the potential
of fruquintinib as a third-line treatment for mCRC.
In accordance with the results obtained from other
studies investigating anti-VEGF/VEGFR drugs, our
study verified that this pathway is an effective target
Table 3 Grade 3 or above treatment-related TEAEs occurring in at least 4% of patients in the phase Ib and the phase II trials




(n=42) Fruquintinib group (n=47) Placebo group (n=24)
Hypertension 9 (21.4) 14 (29.8) 0
HFSR 4 (9.5) 7 (14.9) 0
Diarrhea 4 (9.5) 1 (2.1) 0
Serum sodium decreased 3 (7.1) 0 0
Fatigue 2 (4.8) 2 (4.3) 0
Chest pain 2 (4.8) 0 0
Blood bilirubin increased 1 (2.4) 2 (4.2) 1 (4.2)
AST increased 0 1 (2.1) 1 (4.2)
Platelet count decreased 0 1 (2.1) 1 (4.2)
Blood alkaline phosphatase increased 0 0 2 (8.3)
Myalgia 0 0 1 (4.2)
Coma hepatic 0 0 1 (4.2)
Infection 0 0 1 (4.2)
TEAE treatment-emergent adverse event, HFSR hand-foot skin reaction, AST aspartate aminotransferase
Fig. 1 Trial profile
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for the treatment of mCRC. Similar to the results ob-
tained from the administration of regorafenib and
aflibercept as monotherapies in previously treated
mCRC patients, very few patients reached PR and a
general benefit was mainly observed in patients with
stable disease [10, 15, 16]. However, more than half
of the patients who received fruquintinib showed
tumor shrinkage to different degrees, as demonstrated
in the waterfall plots (Additional file 4), suggesting a
substantial anti-tumor effect for fruquintinib.
Compared with BSC, OS was prolonged for about
2.2 months in patients who received fruquintinib, al-
though no statistically significant difference was ob-
served. The improvement of OS by 2.2 months was
similar to the results of the regorafenib CONCUR trial
[15] that was predominantly conducted in the Chinese
population. Considering the small sample size in the
present phase II trial, it was speculated that a more de-
fined OS benefit might be observed if the sample size
was expanded in future clinical studies. Thus, a phase III
clinical trial (NCT02314819) with OS as the primary
endpoint is currently underway in patients with mCRC
who have failed standard treatment.
The safety profile in the phase II trial was consistent
with that of the patients in the phase Ib trial, and the
AEs included HFSR, hypertension, and proteinuria.
These results were consistent with the results of studies
conducted using other selective VEGFR inhibitors such
as regorafenib [10]. In general, treatment with fruquinti-
nib was well tolerated. As has been reported elsewhere
for other multi-kinase inhibitors, we observed that the
occurrence of grade 3 hypertension was more frequent
in our trial (21.4% of the 42 participants in the phase Ib
trial and 29.8% of the 47 participants in the phase II
trial). Nonetheless, neither grade 4 hypertension nor
hypertensive crisis were reported and no patients dis-
continued treatment. Hypertension is commonly
observed with anti-angiogenic agents, and it could be
managed using standard anti-hypertensive agents if re-
quired. Moreover, some retrospective analyses have sug-
gested that the development of high blood pressure
might be a predictor of good clinical outcome [17, 18].
The incidence of HFSR (64%) in the present study was
slightly higher than that reported by the CORRECT trial
[11]; however, it was consistent with that of the CON-
CUR study [15]. Approximately 15% of the patients were
reported to have developed grade 3 HFSR; however, the
symptoms were clinically manageable by dose interrup-
tion or reduction. Frequencies of treatment modification
(treatment interruption or dose reduction) were similar
between the phase II study (34% and 27%, respectively)
and phase 1b study (47.6%) but were slightly lower than
Fig. 2 Kaplan–Meier curves of progression-free survival (PFS) in the phase II study
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in CONCUR (63% and 40%, respectively) [15] or COR-
RECT (61% and 38%, respectively) [10]. Unexpected
safety issues did not arise, and no patient had bowel per-
foration, which has been related to other VEGF agents.
One limitation of this study was that a predictive
biomarker for fruquintinib was not investigated. How-
ever, considering the lack of a definitive predictive
biomarker for bevacizumab, another anti-VEGF drug
that has been widely used in clinical practice, it is ex-
pected that identifying a predictive biomarker for fru-
quintinib would require some time [18]. In addition,
we did not collect any information on the RAS and
BRAF expression status of the tumors and therefore
could not investigate whether any relationship existed
between the RAS status of the tumor and the efficacy
of fruquintinib. However, it should be noted that pre-
vious studies suggested that the RAS and BRAF status
had no predictive value for outcome in mCRC pa-
tients treated with bevacizumab [19].
Conclusions
In conclusion, based on the present trials, fruquinti-
nib showed good performance in both safety and
efficacy and might be a suitable treatment for mCRC
resistant to standard treatment. The phase III trial
(NCT02314819) that is currently ongoing will help to
achieve a definitive assessment of the safety and effi-
cacy of fruquintinib in mCRC patients who failed the
second-line or above treatment.
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Fig. 3 Kaplan–Meier curves of overall survival (OS) in the phase II study
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